Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.
Adaptimmune Therapeutics stock last closed at $1.58, up 0% from the previous day, and has increased 49.06% in one year. It has overperformed other stocks in the Biotechnology industry by 0.53 percentage points. Adaptimmune Therapeutics stock is currently +276.19% from its 52-week low of $0.42, and -22.93% from its 52-week high of $2.05.
As of Mar 28, 2024, there are 1.48B ADAP shares outstanding. The market capitalization of ADAP is $390.76M. In the last 24 hours, 1.07M ADAP shares were traded.
How to Buy Adaptimmune Therapeutics Stock
Not sure how to invest in Adaptimmune Therapeutics stock? Here's how.
Decide where to buy Adaptimmune Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Adaptimmune Therapeutics stock.
Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Fund your investment account: Choose your payment method and add your info.
Research Adaptimmune Therapeutics stock: The Adaptimmune Therapeutics ticker symbol is ADAP. Is Adaptimmune Therapeutics stock a good investment? Should you buy shares of ADAP? How do ADAP's underlying business fundamentals look? Do top analysts think Adaptimmune Therapeutics is a good buy? Why has ADAP's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if ADAP is a good stock to buy).
Make your ADAP trade: Decide if you will purchase ADAP shares at the current market price or use a limit order to buy ADAP shares at a specific price.
Track your ADAP position: Create a watchlist to watch your new investment in Adaptimmune Therapeutics stock.
Step 1: Decide where to buy Adaptimmune Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy ADAP stock.
A brokerage account is an investment account that allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world markets: From Tech to Industrials, New York to Tokyo — you can fill your portfolio with stocks from the world's leading stock exchanges.
Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in ADAP stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Adaptimmune Therapeutics stock
After you have decided on the best place to buy Adaptimmune Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk and upside.
Adaptimmune Therapeutics Numbers
ADAP Price
$1.58
1w %
17.91%
1y %
49.06%
5y %
-61.27%
P/E
-2.93x
P/B
9.89x
P/S
5.27x
PEG
N/A
Revenue
$60.28M
Earnings
-$113.87M
Fore. Rev. Growth
48.66%
Fore. Earn. Growth
N/A
Market Cap
$390.76M
Next Earnings
May 6, 2024
Next Dividend
N/A
Adaptimmune Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
Last year, ADAP revenue was $60.28M. During the last 5 year, ADAP's revenue has grown by 0.26% per year. This was slower than the Biotechnology industry average of 29.51%.
In the last 12 months, insiders at ADAP have sold more shares than they have bought.
William C. Bertrand Jr., Chief Operating Officer of ADAP, was the latest ADAP insider to sell. They sold $9,152.13 worth of ADAP shares on Jan 17, 2024.
No, Adaptimmune Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your ADAP trade
There are two primary options:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are generally the best for newer investors.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a given price, place a limit order.
Hit the Open Trade button and eToro will execute your order.
If you require additional help buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Adaptimmune Therapeutics share?
As of Mar 28, 2024, it costs $1.58 to buy one share of Adaptimmune Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.79, you can buy 0.5 shares of ADAP.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.